In a retrospective study on 5097 patients with localized breast cancer, HER2 2+ tumor expression was also a poor prognostic factor for RFS (p < 0.0001) compared with HER2 0/1+ in the hormone receptor-positive (PR and/or ER) subgroup, but not in the TNBC subgroup (n = 654) [10]. Here, ERBB2 is linked to neoplasm.